Disability management and rehabilitation for persons with multiple sclerosis

Neural Regeneration Research

Volumn 5, Issue 4, 2010, Pages 301-309

  Khan, Fary ^a,b   Gray, Orla ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Disability management; Effectiveness; Literature review; Multidisciplinary; Multiple sclerosis; Neural regeneration; Neurodegenerative disease; Rehabilitation

Indexed keywords

AMANTADINE; AMINOPYRIDINE DERIVATIVE; AMITRIPTYLINE; BACLOFEN; BOTULINUM TOXIN; CAFFEINE; CANNABINOID; CANNABIS; CARBAMAZEPINE; CLONAZEPAM; DANTROLENE; DESMOPRESSIN; GABAPENTIN; HISTAMINE; IMIPRAMINE; MACROGOL 3350; MODAFINIL; OXYBUTYNIN; PAPAVERINE; POTASSIUM CHANNEL BLOCKING AGENT; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; TIZANIDINE; VARDENAFIL;

ATAXIA; BLADDER DYSFUNCTION; COGNITIVE DEFECT; CONSTIPATION; DAILY LIFE ACTIVITY; DRIVING ABILITY; DYSESTHETIC PAIN; EMPLOYMENT STATUS; ERECTILE DYSFUNCTION; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FUNCTIONAL ASSESSMENT; FUNCTIONAL INDEPENDENCE MEASURE; HUMAN; INTESTINAL DYSMOTILITY; LHERMITTE DUCLOS DISEASE; LONG TERM CARE; MENTAL DISEASE; MOBILIZATION; MULTIPLE SCLEROSIS; MUSCLE SPASM; MYOTONIA; NERVE REGENERATION; NOCTURIA; OVERACTIVE BLADDER; PAIN; PALLIATIVE THERAPY; PHYSICAL MOBILITY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REHABILITATION CARE; REVIEW; SEXUAL DYSFUNCTION; SOCIAL ASPECT; SOCIAL PSYCHOLOGY; SPASTICITY; SYSTEMATIC REVIEW; TRIGEMINUS NEURALGIA; VISUAL DISORDER; WEAKNESS;

EID: 77949368042     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374     Document Type: Review

References (84)

1. World Health Organization. Atlas: Country Resources for Neurological Disorders. Geneva: World Health Organization. 2004.
2. Wade DT. Measurement in Neurological Rehabilitation. Oxford University Press. 1992.
3. World Health Organization (WHO). The International Classification of Functioning, Disability and Health (ICF). Geneva: WHO. 2001.
4. Khan F, Pallant JF. Use of International Classification of Functioning, Disability and Health (ICF) to describe patient-reported disability in multiple sclerosis and identification of relevant environmental factors. J Rehabil Med. 2007;39:63-70.
5. Khan F, Pallant JF. Use of the International Classification of Functioning, Disability and Health (ICF) to identify preliminary comprehensive and brief core sets for multiple sclerosis. Disabil Rehabil. 2007;29:205-213.
6. Thompson AJ. The effectiveness of neurological rehabilitation in multiple sclerosis. J Rehabil Res Dev. 2000;37:455-461.
7. National Collaborating Centre for Chronic Conditions. Multiple Sclerosis: Management of Multiple Sclerosis in Primary and Secondary Care. Clinical Guidelines-8. 2003.
8. Kraft GH, Johnson KL, Yorkston K, et al. Setting the agenda for multiple sclerosis rehabilitation research. Mult Scler. 2008;14: 1292-1297.
9. Hobart JC, Lamping DL, Freeman JA, et al. Evidence based measurement: which disability scale for neurological rehabilitation? Neurology. 2001;57:639-644.
10. Rossiter DA, Edmondson A, al-Shahi R, et al. Integrated care pathways in multiple sclerosis rehabilitation: completing the audit cycle. Mult Scler. 1998;4(2):85-89.
11. Khan F, Pallant JF, Turner-Stokes L. Use of goal attainment scaling in inpatient rehabilitation for persons with multiple sclerosis. Arch Phys Med Rehabil. 2008;89(4):652-659.
12. Wade DT. Evidence relating to goal planning in rehabilitation. Clin Rehabil. 1998;12(4):273-275.
13. Khan F, Turner Stokes L, Ng L, et al. Multidisciplinary rehabilitation for adults with multiple sclerosis (review). Cochrane Database Syst Rev. 2007;(2):CD006036.
14. Khan F, Pallant JF, Brand C, et al. Effectiveness of rehabilitation intervention in persons with multiple sclerosis: a randomized controlled trial. J Neurol Neurosurg Psychiatry. 2008;79: 1230-1235.
15. Freeman JA, Langdon DW, Hobart JC, et al. Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? Neurology. 1999;52:50-56.
16. Khan F, Turner-Stokes L, Stevermuer T, et al. Multiple sclerosis rehabilitation outcomes: analysis of a national casemix data set from Australia. Mult Scler. 2009;15(7):869-875.
17. Ramp M, Khan F, Misajon RA, et al. Rasch analysis of the Multiple Sclerosis Impact Scale MSIS-29. Health Qual Life Outcomes. 2009;7:58.
18. Rietberg MB, Brooks D, Uitdehaag BM, et al. Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev. 2005;(1): CD003980.
19. Stultjens EM, Dekker J, Bouter LM, et al. Occupational therapy for multiple sclerosis. Cochrane Database Syst Rev. 2003;(3): CD003608.
20. Baker NA, Tickle-Degnen L. The effectiveness of physical, psychological, and functional interventions in treating clients with multiple sclerosis: a meta-analysis. Am J Occup Ther. 2001;55(3): 324-331.
21. Thomas PW, Thomas S, Hillier C, et al. Psvchological interventions for multiple sclerosis. Cochrane Database Syst Rev 2006;(1):CD004431.
22. Thompson AJ. Symptomatic management and rehabilitation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;71:22-27.
23. Khan F, McPhail T, Brand C, et al. Multiple sclerosis: disability profile and quality of life in an Australian community cohort. Int J Rehabil Res. 2006;29(2):87-96.
24. Aronson KJ, Cleghorn G, Goldenberg E. Assistance arrangements and use of services among persons with multiple sclerosis and their caregivers. Disabil Rehabil. 1996;18(7): 354-61.
25. Khan F, Pallant J. Chronic pain in multiple sclerosis: prevalence, characteristics and impact on quality of life in an Australian community cohort. J Pain. 2007;8(8):614-623.
26. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and Multiple Sclerosis: Evidence-based Management Strategies for Fatigue in Multiple Sclerosis. Washington, DC: Paralysed Veterans of America. 1998.
27. MacAllister WS, Krupp LB. Multiple sclerosis- related fatigue. In: Brown TR, Kraft GH, eds. Physical Medicine and Rehabilitation Clinics of North America: Multiple Sclerosis: A Paradigm Shift. Philadelphia: WB Saunders. 2005.
28. Solari A, Uitdehaag B, Guiliani G, et al. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev. 2002;(4):CD001330.
29. Pucci E, Branas P, D'Amico R, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007;(1): CD002818.
30. Gillson G, Tichard TL, Smith RB, et al. A double blind pilot study of the effect of Prokarin on fatigue in multiple sclerosis (abstract). Mult Scler. 2002;8:30-35.
31. Norvedt MW, Riise T, Frugard J, et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Mult Scler. 2007;13:106-112.
32. de Seze M, Ruffion A, Denys P, et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007;13:915-928.
33. Khan F, Pallant J, Shea T, et al. Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian cohort. Disabil Rehabil. 2009;31(19):1567-1576.
34. Hussain I, Fowler C. The cause and management of bladder, sexual and bowel symptoms. In: Hawkins CP, Wolinsky JS, eds. Principles of Treatment in Multiple Sclerosis. Oxford: Butterworth-Heinemann. 2000:258-281.
35. Multiple Sclerosis Council for Clinical Practice Guidelines. Urinary Dysfunction and Multiple Sclerosis. Evidence Based Management Strategies for Urinary Dysfunction in Multiple Sclerosis. Washington, DC. The Paralysed Veterans of America. 1999.
36. Nicholas RS, Friede T, Hollis S, et al. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev. 2009;(1):CD004193.
37. Jepson RG, Mihaljevic L, Craig J. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2004;(1): CD001321.
38. Hoverd PA, Fowler CJ. Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998; 65:778-780.
39. Brady CM, DasGupta R, Dalton C, et al. An open label pilot study of cannabis based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler. 2004;10:425-433.
40. Vahtera T, Haaranen M, Viramo- Koskela AL, et al. Pelvic floor rehabilitation is effective in patients with multiple sclerosis. Clin Rehabil. 1997;11:211-219.
41. Chia YW, Fowler C, Kamm M, et al. Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. J Neurol. 1995;242:105-108.
42. Nordenbo A, Anderson J, Anderson J. Disturbances of anorectal function in multiple sclerosis. J Neurol. 1996;243:445-451.
43. Fowler CJ, Henry MM. Gastrointestinal dysfunction in multiple sclerosis. Mult Scler. 1999;6:59-61.
44. Gruenwald I, Vardi Y, Gartman I, et al. Sexual dysfunction in females with multiple sclerosis: quantitative sensory testing. Mult Scler. 2007;13:95-105.
45. Urciuoli R, Cantisani TA, CarliniI M, et al. Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database Syst Rev. 2004;(2):CD001784.
46. Richardson D. Evaluation of intervention in the management of spasticity: treatment goals and outcome measures. In: Shean G, Barnes MP, eds. Spasticity Rehabilitation. London, UK: Churchill Communications Europe Limited. 1998.
47. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev. 2003;(4): CD001332.
48. Haselkorn JK, Loomis S. Multiple sclerosis and spasticity. In: Brown TR, Kraft GH, eds. Physical Medicine and Rehabilitation Clinics of North America: Multiple Sclerosis: A Paradigm Shift. Philadelphia: WB Saunders. 2005.
49. Thompson AJ. Spasticity rehabilitation: a rational approach to clinical management. In: Shean G, Barnes MP, eds. Spasticity Rehabilitation. London, UK : Churchill Communications Europe Limited. 1998.
50. Mohammed I, Hussain A. Intrathecal baclofen withdrawal syndrome- a life-threatening complication of baclofen pump: a case report. BMC Clin Pharmacol. 2004;4:6.
51. Mills RJ, Yap L, Young CA. Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev. 2007;(1):CD005029.
52. Schuurman PR, Bosch DA, Bossuyt PM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Eng J Med. 2000;342:461-468.
53. Boivie J. Central pain. In: Wall PD, Melzack R, eds. Textbook of Pain. New York, USA: Churchill Livingstone. 1999:879-914.
54. Ehde DM, Osborne TL, Jensen MP. Chronic pain in persons with multiple sclerosis. In: Brown TR, Kraft GH, eds. Physical Medicine and Rehabilitation Clinics of North America: Multiple Sclerosis: A Paradigm Shift. Philadelphia: WB Saunders. 2005.
55. Houtchens MK, Richert JR, Sami A, et al. Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler. 1997;3: 250-253.
56. Frighetto L, De Salles A, Smith ZA, et al. Noninvasive linear accelerator radiosurgery as the primary treatment for trigeminal neuralgia. Neurology. 2004;62:660-662.
57. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized controlled trial of cannabis based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812-819.
58. Rao SM, Leo GJ, Berbnardin L, et al. Cognitive dysfunction in multiple sclerosis I. Frequency, patterns and predictions. Neurology. 1991;41:685-691.
59. Pepping M, Ehde D. Neuropsychological evaluation and treatment of multiple sclerosis: the importance of a neurorehabilitation focus. In: Brown TR, Kraft GH, eds. Physical Medicine and Rehabilitation Clinics of North America: Multiple Sclerosis: A Paradigm Shift. Philadelphia: WB Saunders. 2005.
60. Frankel D. Multiple sclerosis. In: Umphred DA, ed. Neurological Rehabilitation. 5th ed. St Louis: Mosby Elsievier. 2007:709-731.
61. Plohmann AM, Kappos L, Ammann W, et al. Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998;64:455-462.
62. Geisler MW, Sliwinski M, Coyle PK, et al. The effects of Amantadine and Pemoline on cognitive functioning in multiple sclerosis. Arch Neurol .1996;53:185-188.
63. Starck M, Albrecht H, Pollmann W, et al. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol. 1997;244: 9-16.
64. Sapir S, Pawlas AA, Ramig LO, et al. Effects of intensive phonatory respiratort treatment (LSVT) on voice in two individuals with multiple sclerosis. J Med Speech Lang Pathol. 2001;9: 141-151.
65. Calcagno P, Ruoppolo G, Grasso MG, et al. Dysphagia in multiple sclerosis-prevalence and prognostic factors. Acta Neurol Scand. 2002;105:40-43.
66. De Pauw A, Dejaeger E, D'hooghe B, et al. Dysphagia in multiple sclerosis. Clin Neurol Neurosurg. 2002;104:345-351.
67. Patten SB, Metz LM, Reimer MA. Biopsychosocial correlates of life time major depression in multiple sclerosis population. Mult Scler. 2000;6:115-120.
68. Katon W, Ciechanowski P. Impact of major depression on chronic medical illness. J Psychsom Res. 2002;53:859-863.
69. Khan F, Pallant J, Brand C. Caregiver strain and factors associated with caregiver self-efficacy and quality of life in a community cohort with multiple sclerosis. Disabil Rehabil. 2007;29:1241-1250.
70. Benedict RH, Fischer JS, Archbald CJ, et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol. 2002;16:381-397.
71. Mohr DC, Boudewn AC, Goodin DE, et al. Comparative outcomes for individual cognitive behaviour therapy, supportive expressive group psychotherapy and sertraline for treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001;69:942-949.
72. Mohr DC, Likosky W, Betagnolli A, et al. Telephone administered cognitive behaviour therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol. 2000;68: 356-361.
73. Sutherland G, Anderson MB. Exercise and multiple sclerosis: physiological, psychological and quality of life issues. J Sports Med Phys Fitness. 2001;41:421-432.
74. Babyak M, Blumenthal JA, Herman S, et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med. 2000;62:633-638.
75. Brown T, Kraft GH. Exercise and Rehabilitation for individuals with multiple sclerosis. In: Brown TR, Kraft GH, eds. Physical Medicine and Rehabilitation Clinics of North America: Multiple Sclerosis: A Paradigm Shift. Philadelphia: WB Saunders. 2005.
76. White AT. Exercise and MS: Challenges and opportunities. Mult Scler Q Rep. 2004;23:18-20.
77. Kraft GH. Foreword. Phys Med Rehabil Clin N Am. 1998;9(3): xi-xiii.
78. Hutchinson B. Rehabilitation interventions for people with multiple sclerosis. Mult Scler Q Rep. 2004;23:3-11.
79. LaBaan MM, Martin T, Pech J, et al. Physical and occupational therapy in the treatment of patients with multiple sclerosis. Phys Med Rehabil Clin N Am. 1998;9:603-614 (vii).
80. Bronnum-Hansen H, Hansen T, Kock-Henriksen N, et al. Fatal accidents among Danes with multiple sclerosis. Mult Scler. 2006;12:329-332.
81. Schulthesis MT, Garay E, Millis SR, et al. Motor vehicle crashes and violations among drivers with multiple sclerosis. Arch Phys Med Rehabil. 2002;83:1175-1178.
82. Johnson KL, Fraser RT. Mitigating the impact of multiple sclerosis on employment. Phys Med Rehabil Clin N Am. 2005;16:771-783.
83. Rumrill P. Employment Issues and Multiple Sclerosis. New York, USA: Demos Publications. 1996.
84. Khan F, Ng L, Turner-Stokes L. Effectiveness of vocational rehabilitation intervention on the return to work and employment of persons with multiple sclerosis. Cochrane Database Syst Rev. 2009;(1):CD007256.